CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 5 enrolled
Drug / intervention
Durvalumab +1 moredrug
Likely dose
Durvalumab 1500 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04301778
NCT04301778Phase 2Completed
CompareCT.gov

A Phase II Study of Durvalumab (MEDI4736) in Combination With a CSF-1R Inhibitor (SNDX-6532) Following Chemo or Radio-Embolization for Patients With Intrahepatic Cholangiocarcinoma.

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins·interventional·Posted Mar 10, 2020·Updated Mar 13, 2026

In Brief

A Phase 2 clinical trial evaluating Durvalumab and SNDX-6352 for Unresectable Intrahepatic Cholangiocarcinoma. Completed, enrolled 5 participants across 1 site.

Detailed Summary

The purposed of this research is to study the safety and clinical activity of the combination of durvalumab and a CSF-1R inhibitor (SNDX-6352) in people with Intrahepatic Cholangiocarcinoma.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsUnresectable Intrahepatic Cholangiocarcinoma
CountriesUnited States
CollaboratorsSyndax Pharmaceuticals, AstraZeneca

Timeline

Phase 2CompletedFinished
202120222023202420252026
First PostedMar 10, 2020
Enrollment StartAug 24, 2021
Primary CompletionNov 4, 2022
Study CompletionFeb 6, 2024
TodayJul 2, 2026
Enrollment to primary: 1.2 yearsPosted 6.3 years ago

Interventions

Durvalumabdrug

1. Durvalumab - 1500 mg via IV infusion over 60 minutes (-5/+10 min) on day 1 of each 28-day cycle (every 4 weeks). 2. Drug - 1500mg IV

SNDX-6352drug

1. SNDX-6352 - 3mg/kg via IV infusion over 30 minutes (-5/+10 min) on days 1 and 15 of each 28-day cycle (every 2 weeks), starting with cycle 2 (not given during cycle 1). 2. Drug - 3mg/kg IV